Andrea Serafin, Alessandro Cellini, Chiara Adele Cavarretta, Valeria Ruocco, Francesco Angotzi, Ivan Zatta, Federica Frezzato, Laura Bonaldi, Annalisa Martines, Stefano Pravato, Francesco Piazza, Livio Trentin, Andrea Visentin
{"title":"Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens","authors":"Andrea Serafin, Alessandro Cellini, Chiara Adele Cavarretta, Valeria Ruocco, Francesco Angotzi, Ivan Zatta, Federica Frezzato, Laura Bonaldi, Annalisa Martines, Stefano Pravato, Francesco Piazza, Livio Trentin, Andrea Visentin","doi":"10.1111/bjh.19517","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax-based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA-CLL13), specifically focus on this topic while real-word evidence is missing. In our real-life retrospective study conducted on 61 patients with CLL and treated with venetoclax-based regimens in any therapeutic line, we documented a remarkable lower progression-free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.</p>\n </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 1","pages":"189-193"},"PeriodicalIF":3.8000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19517","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax-based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA-CLL13), specifically focus on this topic while real-word evidence is missing. In our real-life retrospective study conducted on 61 patients with CLL and treated with venetoclax-based regimens in any therapeutic line, we documented a remarkable lower progression-free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.
虽然复杂核型（CK）在接受化疗免疫疗法的慢性淋巴细胞白血病（CLL）患者中的不利预后作用已得到明确，但它对接受新型靶向药物，尤其是以 Venetoclax 为基础的治疗方案的患者预后的影响仍有待解决。事实上，只有少数研究利用临床试验数据（如 MURANO、CLL14、GAIA-CLL13）专门研究了这一问题，而实际证据尚缺。在我们对 61 例 CLL 患者进行的真实回顾性研究中，我们记录了同时患有 CK 和高 CK 的患者的无进展生存期明显较低，而在我们的研究人群中，总反应率（包括完全缓解和部分缓解）和总生存期并未受到 CK 的影响。
期刊介绍：
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
